Causes and long-term course of ototoxicity in pediatric medulloblastoma and ependymoma patients – cumulative platinum and cochlear irradiation dose matter
Year: 2026
Type: preprint
Abstract: Purpose This study aimed to define dose-dependent risk factors and thresholds for ototoxicity after cisplatin chemotherapy and radiotherapy (RT). Methods Patients from the HIT2000 trial receiving first-line treatment for medulloblastoma (MB) or ependymoma (EP) were eligible. Treatment details (incl. cochlear irradiation dose [CID]) and audiological outcome were analyzed. Ototoxicity was graded using the HIT ototoxicity grading system (HIT). Results Courses of 101 patients were analyzed. Median audiology follow-up was 6 years [range: 1.0–18.1 years]. Ototoxicity grade ≥ 1 was diagnosed for n = 66 patients (65.4%). Univariable analyses revealed differing distributions of ototoxicity regarding histology (classical medulloblastoma [CMB]: 50/65, large-cell/anaplastic medulloblastoma [LCAMB]: 3/3, desmoplastic medulloblastoma [DMB]/medulloblastoma with extensive nodularity [MBEN]: 8/12, EP: 5/21; p < 0.001), tumor localization (supratentorial: 3/9, infratentorial: 63/92; p < 0.001), metastatic status (non-metastatic disease [M0]: 46/77, metastatic disease [M+]: 20/24; p = 0.003), radiation field (craniospinal irradiation [CSI]: 59/75, local RT: 6/21, no RT: 1/5; p < 0.001), CID (p < 0.001) and cumulative cisplatinum dose (p = 0.02). Multivariable analyses confirmed the impact of cumulative cisplatinum dose (p = 0.004) and CID (p = 0.046). Receiver operating characteristic analyses defined cut-offs for high risk of ototoxicity grade ≥ 1 (cisplatinum: 70 mg/m2 body surface area [BSA], CID: 37.5 Gy): each 1 mg/m2 BSA increase in cisplatinum dose raised risk by 4%, and each 1 Gy increase in CID raised risk by 4.6%. Conclusions Ototoxicity affects a majority of children receiving adjuvant treatment for MB and EP. To avoid disabilities and negative effect on quality of life, dosage of cisplatinum and radiotherapy should be scrutinized and reduced whenever possible.
Source: Research Square
Authors: Elif Brecht, Annika Hardt, Rolf-Dieter Kortmann, Rudolf Schwarz, Beate Timmermann, Brigitte Bison, Monika Warmuth-Metz, Katja von Hoff, Andre O. von Bueren, Nicolas U. Gerber, Hans O. Pinnschmidt, Gudrun Fleischhack, Stephan Tippelt, Torsten Pietsch, Christian Hagel, Stefan M. Pfister, Dominik Sturm, Martin Mynarek, Stefan Rutkowski, Denise Obrecht-Sturm
Institutions: University Medical Center Hamburg-Eppendorf, Leipzig University, Essen University Hospital, University Hospital Augsburg, Universitätsklinikum Würzburg, Charité – Universitätsmedizin Berlin, University Hospital of Geneva, University Hospital Zurich, University of Bonn, Heidelberg University
Language: English
Subfield: Sensory Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Funder: Deutsche Kinderkrebsstiftung
OpenAlex ID: W7225908744
